Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.
Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S; Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Poole-Wilson PA, et al. Among authors: hildebrandt p. Lancet. 2004 Sep 4-10;364(9437):849-57. doi: 10.1016/S0140-6736(04)16980-8. Lancet. 2004. PMID: 15351192 Clinical Trial.
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.
Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, Keren A, Motro M, Moyé LA, Otterstad JE, Pratt CM, Ponikowski P, Rouleau JL, Sestier F, Winkelmann BR, Young JB; Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators. Torre-Amione G, et al. Among authors: hildebrandt p. Lancet. 2008 Jan 19;371(9608):228-36. doi: 10.1016/S0140-6736(08)60134-8. Lancet. 2008. PMID: 18207018 Clinical Trial.
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN).
Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, Soler-Soler J, Scherhag A, Lutiger B, Rydén L. Remme WJ, et al. Among authors: hildebrandt p. Cardiovasc Drugs Ther. 2004 Jan;18(1):57-66. doi: 10.1023/B:CARD.0000025756.32499.6f. Cardiovasc Drugs Ther. 2004. PMID: 15115904 Clinical Trial.
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ; CARMEN investigators and co-ordinators. Komajda M, et al. Among authors: hildebrandt p. Eur J Heart Fail. 2004 Jun;6(4):467-75. doi: 10.1016/j.ejheart.2003.12.019. Eur J Heart Fail. 2004. PMID: 15182773 Free article. Clinical Trial.
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; ESSENTIAL Investigators. Metra M, et al. Eur Heart J. 2009 Dec;30(24):3015-26. doi: 10.1093/eurheartj/ehp338. Eur Heart J. 2009. PMID: 19700774 Free PMC article. Clinical Trial.
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.
Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Gluud C; CLARICOR Trial Group. Jespersen CM, et al. Among authors: hildebrandt p. BMJ. 2006 Jan 7;332(7532):22-7. doi: 10.1136/bmj.38666.653600.55. Epub 2005 Dec 8. BMJ. 2006. PMID: 16339220 Free PMC article. Clinical Trial.
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL.
Ceconi C, Freedman SB, Tardif JC, Hildebrandt P, McDonagh T, Gueret P, Parrinello G, Robertson M, Steg PG, Tendera M, Ford I, Fox K, Ferrari R; BEAUTIFUL Echo-BNP Investigators. Ceconi C, et al. Among authors: hildebrandt p. Int J Cardiol. 2011 Feb 3;146(3):408-14. doi: 10.1016/j.ijcard.2010.10.125. Epub 2010 Nov 26. Int J Cardiol. 2011. PMID: 21112101 Clinical Trial.
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; CLARICOR Trial Group. Kastrup J, et al. Among authors: hildebrandt p. Eur Heart J. 2009 May;30(9):1066-72. doi: 10.1093/eurheartj/ehp049. Epub 2009 Mar 6. Eur Heart J. 2009. PMID: 19270316 Free article. Clinical Trial.
627 results